CHANGE IN RATINGS
downgraded at Barclays from Overweight to Equal-weight. Valuation call, based on a $27 price target. Stock is trading at a record high premium to the S&P 500.
Canadian National Railway
upgraded at JPMorgan to Overweight from Neutral based on cost reductions and leverage to potential improvement in North American economy. Expect near-term earnings to hold up well and note limited exposure to coal and U.S. legislation risks. Price target raised to $50 from $43.
downgraded at JPMorgan to Neutral from Overweight. Expect volume and earnings to lag the rest of the rail group due to weakening coal volumes. Also note potential rate structure declines linked to new rail legislation. Price target trimmed to $41 from $45.
Research In Motion
upgraded at UBS. Rating raised to Buy from Neutral. Price target raised to $90 from $65. Fiscal 2010 EPS raised to $3.77 from $3.76.
downgraded at Goldman Sachs to Sell from Neutral based on concerns over Lunesta trends. Physician survey indicates a greater Lunesta decline than anticipated. Price target at $15.
upgraded at Goldman Sachs to Buy from Sell based on improving oil sands economics. Expect higher crude oil prices during the second half of 2009 and into 2010. Price target raised to $33 from $25.
STOCK COMMENTS / EPS CHANGES
estimates, target increased at UBS to $100. Estimates raised because of stronger production rates and lower costs. Buy rating.
estimates, target cut at UBS to $64. Estimates reduced because of the weaker economy and reimbursement issues. Buy rating.
estimates, target reduced at Barclays to $24. Estimates lowered because of lower expected membership levels. Equal-weight rating.
estimates, target raised at UBS to $16. Estimates increased to reflect higher margins. Neutral rating.
estimates, target raised at Merrill/BofA to $13. Estimates boosted to reflect lower costs and higher operating rates. Underperform rating.
estimates cut at UBS through 2010. Company seeing poor life insurance trends. Neutral rating and $9.50 price target.
numbers increased at Barclays to $9. Estimates raised to reflect a larger tax credit and lower capital spending. Underweight rating.
estimates, target raised at Morgan Stanley to $46. Estimates increased to reflect lower costs. Overweight rating.
numbers raised at Barclays through 2010. Company is cutting costs faster than expected. Equal-weight rating and new $5.50 price target.
estimates, target cut at Barclays. Estimates lowered through 2010. Neptune operation is disappointing. Overweight rating and new $43 price target.
numbers raised at Barclays to $15. Estimates also increased, to match higher sales demand. Company is also taking market share. Equal-weight rating.
numbers raised at Merrill/BofA through 2010, Merrill Lynch/Bank of America said. Company is realizing higher margins, though sales visibility remains poor. Neutral rating.
numbers increased at Barclays to $28. Estimates also raised, to reflect cost-cutting and merger synergies. Overweight rating.
estimates increased through 2010, target raised at Barclays. Company is cutting costs, though sales came in lower than expected. Underweight rating and new $14 price target.
numbers boosted at Merrill/BofA to $126. Estimates also increased, to reflect strong momentum in the U.S. Buy rating.
estimates, target raised at Merrill/BofA to $17. Estimates also increased, given the company's higher realized margins. Neutral rating.
numbers raised at Morgan Stanley to $185. Estimates also boosted, to reflect strong enrollment growth. Equal-weight rating.
numbers raised at UBS through 2010. Company is seeing steady ad demand and keeping a lid on costs. Neutral rating and new $20 price target.
estimates lowered through 2010, target cut at Barclays Capital. Company could miss production expectations and will likely buy back less stock. Equal-weight rating and new $89 price target.
This article was written by a staff member of TheStreet.com.